Abstract:Judith Wellens, 1, 2 Eva Vissers, 1 Christophe Matthys, 3, 4 Séverine Vermeire, 1, 2 João Sabino 1, 2 1 KU Leuven Department of Chronic Diseases and Metabolism, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium; 2 Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium; 3 Clinical Nutrition Unit, Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium; 4 KU Leuven Department of Chronic Diseases and Metabolism, Clinical and Experimental Endocrinology, Leuven, Belgium Correspondence: João Sabino, Email Inflammatory bowel diseases (IBD) are chronic and incurable conditions of the gastro-intestinal tract with an increasing incidence and prevalence worldwide. Common symptoms are abdominal pain, diarrhea, and weight loss. Despite recent advances in medical management, many patients fail to achieve clinical remission and healing of the mucosa of the bowel. The cause is thought to involve an inappropriate reaction of the immune system, the microbiome and the environment in genetically susceptible individuals, leading to chronic bowel inflammation. Evidence is emerging that diet is a key environmental factor that might influence disease onset and course, and therefore may become a therapeutic strategy to mitigate inflammation and symptoms. Since IBD is a heterogeneous disease on a clinical and a molecular level, personalizing dietary advice could be the crucial factor to achieve long-lasting changes in dietary behaviors that could not only improve nutritional status but also tackle gut inflammation and abdominal symptoms on an individual level. In this review, we first discuss different aspects of personalized nutrition, namely the level, focus, and scope of personalized dietary regimens. Then, we provide a framework for the different goals of nutritional therapy in IBD and current evidence for personalized dietary approaches. Lastly, we discuss the need for adequate trial designs, access to the right data types and the bioinformatic tools that are necessary to develop algorithms that will allow us to move from general "healthy eating" advice to truly personalized nutritional plans for the individual IBD patient. Keywords: inflammatory bowel disease, precision nutrition, nutritional therapy, personalized nutrition Inflammatory bowel diseases (IBD) are chronic and incurable inflammatory conditions of the gastrointestinal tract encompassing two main clinical entities: Crohn's disease (CD) and ulcerative colitis (UC). 1 Both conditions are thought to originate from an inappropriate immune response to microbial and/or environmental factors in a genetically susceptible host. 1 The stunning rise in incidence of IBD in Asian countries and the Middle East suggests that lifestyle and dietary changes towards a "Westernized diet" play an important role in disease pathogenesis. The Westernized diet is hallmarked by an increased consumption of animal fat, red and processed meat, and a reduced intake of fibre. 2–4 Indeed, a high dietary intake of total fats, polyunsaturated fatty acids (PUFAs), omega-6 fatty acids, and meat has been associated with an increased risk of CD and UC in observational studies. 5 It should, however, be noted that many associations have been inconsistent, which is possibly due to poor trial design, differences in study populations or retrospective designs that suffer from recall bias. 6 Importantly, besides these broad categories of nutritional elements, there is also the indisputable rise in ultra-processed food (UPF) consumption, which has recently been associated with an increase in incident cases of persons with IBD, and particularly CD. 7–9 Emulsifiers are a category of food additives commonly used in UPFs to improve food texture, palatability, and shelf life. Emulsifiers have been associated with IBD, both in animal and laboratory studies. 10 Polysorbates for example affect permeability of epithelial cell cultures, 11 and induce intestinal inflammation in susceptible mice. 10,12 For other emulsifiers such as carrageenan, administration through drinking water in guinea pigs resulted in colonic ulcerations resembling the ulcerations seen in humans. In colonic cell lines, this emulsifier induced tumor necrosis factor (TNF) production. 13,14 Moreover, a study assessing the effect of carboxymethyl cellulose (CMC) in healthy volunteers found a perturbation in the faecal microbiota with a reduced diversity and changes in the metabolome with, amongst other changes, a decrease in short chain fatty acids. 15 Interestingly, although this was a small study, clear intersubject -Abstract Truncated-

Understanding patient variability to biologic treatments in inflammatory bowel disease

P479 Trends in Medication Use and Treatment Patterns in Chinese Patients with Inflammatory Bowel Diseases: A Multicenter Cohort Study from 1999 to 2020

Inflammatory bowel disease evolution in the past two decades: a chronological multinational study

Clinical Presentation of Inflammatory Bowel Disease： a Hospital Based Retrospective Study of 379 Patients in Eastern China

Clinical Characteristics of 379 Patients with Inflammatory Bowel Disease

P467 Perception Gap Between Patients with Inflammatory Bowel Disease (IBD) and Physicians in China: A Cross-sectional Study

P1156 Characteristics and outcomes of over a million Inflammatory Bowel Disease patients in seven countries: a multinational cohort study

Initial medical and surgical management of inflammatory bowel disease in the biologic era: A comparison between the United States and China

P1182 What has changed in Inflammatory Bowel Disease during last three decades?

Inflammatory Bowel Disease: A Comprehensive Analysis of Molecular Bases, Predictive Biomarkers, Diagnostic Methods, and Therapeutic Options

Gastrointestinal Conditions: Inflammatory Bowel Disease.

P1131 Epidemiological Characteristics of Inflammatory Bowel Diseases in The Last Decade: Multi-Center Türkiye Data

P1112 Clinical features between familial versus sporadic inflammatory bowel disease: a retrospective single centre study

P606 A Retrospective Observational Study of Patterns of Biologic Drug Change in Inflammatory Bowel Disease

Early Course of Inflammatory Bowel Disease in a Population-Based Inception Cohort Study From 8 Countries in Asia and Australia

Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunities

The epidemiology and the pathogenesis of inflammatory bowel disease

A comprehensive review and update on Crohn's disease

TRENDS IN INFLAMMATORY BOWEL DISEASE INCIDENCE AND PREVALENCE ACROSS EPIDEMIOLOGIC STAGES: A GLOBAL SYSTEMATIC REVIEW WITH META-ANALYSIS

P347 A Trend Analysis of Inflammatory Bowel Disease in Non-Endemic Era (1993-2023)

Personalized Dietary Regimens for Inflammatory Bowel Disease: Current Knowledge and Future Perspectives